The Aussie biotech betting on life after Ozempic

Former pharma executive Karinza Phoenix is raising $5 million and preparing an ASX listing as Myopharm advances a diabetes drug it hopes can complement the GLP-1 giants. Karinza Phoenix hasn’t found it hard raising the $6 million that’s got her biotech firm, Myopharm, onto the fast-track approval process for its Type 2 diabetes drug. “How […]

Why Phil Kearns quit the ASX for a country concrete startup

A chance conversation on a golf course has drawn the former Wallaby and listed-company CEO into a regional manufacturing venture aiming to decarbonise one of the world’s dirtiest industries. Former Wallaby great Phil Kearns was no great fan of Scope 3 emissions requirements and all the other rigmarole he’d had to go through as CEO […]